In a regulatory filing, West Pharmaceutical (WST) stated, “On December 9, 2024, the Board of Directors approved a share repurchase program authorizing the repurchase of up to 550,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2025. The company’s previously-authorized share repurchase program is expected to expire by December 31, 2024.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical price target raised to $355 from $350 at BofA
- West Pharmaceutical initiated with a Peer Perform at Wolfe Research
- West Pharmaceutical upgraded to Buy from Neutral at UBS
- West Pharmaceutical Expands Board with New Director
- West Pharmaceutical Services (WST) Reveals Q4 Dividend: Here’s the Essential Information